Transketolase serves a poor prognosticator in esophageal cancer by promoting cell invasion via epithelial-mesenchymal transition

Journal of Cancer

Volumn 7, Issue 13, 2016, Pages 1804-1811

  Chao, Yin Kai ^a   Peng, Ta Lun ^b   Chuang, Wen Yu ^a   Yeh, Chi Ju ^a   Li, Yan Liang ^b   Lu, Ya Ching ^b   Cheng, Ann Joy ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cell invasion; Epithelial mesenchymal transition; Esophageal cancer; Prognosis; Transketolase

Indexed keywords

FIBRONECTIN; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE CELL ADHESION MOLECULE; PLAKOGLOBIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSKETOLASE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL VIABILITY; CHEMORADIOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS INHIBITION; MIDDLE AGED; MIGRATION INHIBITION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 85003905044     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.15467     Document Type: Article

References (26)

1. Garber K. Energy boost: the Warberg effect returns in a new theory of cancer. J Natl Cancer Inst. 2004; 96: 1805-6.
2. Upadhyay M, Samal J, Kandpal M, et al. The Warberg effect: insight from the past decade. Pharmacol Ther. 2013; 137: 318-30.
3. Zhao J, Zhong CJ. A review on research progress of transkeolase. Neurosci Bull. 2009; 25: 94-9.
4. Fritz P, Coy JF, Murdter TE, et al. TKTL-1 expression in lung cancer. Pathol Res Pract. 2012; 208: 203-9.
5. Sun W, Liu Y, Glazer CA, et al. TKTL1 is activated by promoter hypomethyation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010; 16: 857-66.
6. Krockenberger M, Engel J, Schmidt M, et al. Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 2010; 30: 1653-9.
7. Kayser G, Sienel W, Kubitz B, et al. Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathol. 2011; 43: 719-24.
8. Diaz-Moralli S, Tarrando-Castellamau M, Alenda C, et al. Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011; 6: e25323.
9. Yuan W, Wu S, Guo J, et al. Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther. 2010; 9: 710-6.
10. Chen H, Yue JX, Yang SH, et al. Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009; 28: 43.
11. Ricciardelli C, Lokman NA, Cheruvu S, et al. Trahsketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin Exp Metastasis. 2015; 32: 441-55.
12. Xu IM, Lai RK, Lin SH, et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci USA. 2016; E725-34.
13. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014; 6: 112-20.
14. Wuu KD, Cheng MY, Wang-Wuu S, et al. Chromosome analysis on a cell line (CE38T/VGH) derived from a human esophageal carcinoma. Cancer Genet Cytogenet. 1986; 20: 279-85.
15. Chen YJ, Lee LY, Chao YK, et al. DSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEF-myc /cyclinD1 /MMP signaling pathway. PLoS One. 2013, 8: e60488.
16. Chiu CC, Lee LY, Li YC, et al. Grp78 as a therapeutic target for refractory head-neck cancer with CD24-CD44+ stemness phenotype. Cancer Gene Ther. 2013; 20: 606-15.
17. Chao YK, Chuang WY, Yeh CJ, et al. Prognostic significance of high podoplanin expression after chemoradiotherapy in esophageal squamous cell carcinoma patients. J Surg Oncol. 2012; 105: 183-8.
18. Savagner P. Epithelial-mesenchymal transitions: from cell plasticity to concept elasticity. Curr Top Dev Biol. 2015; 112: 273-300.
19. Banyard J, Bielenberg DR. The role of EMT and MET in cancer dissemination. Connect Tissue Res. 2015; 56: 403-13.
20. Baulida J, García de Herreros A. Snail1-driven plasticity of epithelial and mesenchymal cells sustains cancer malignancy. Biochim Biophys Acta. 2015; 1856: 55-61.
21. Phillips S, Kuperwasser C. SLUG: Critical regulator of epithelial cell identity in breast development and cancer. Adh Migr. 2014; 8: 578-87.
22. Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014; 35: 7335-42.
23. Liu X, Yun F, Shi L, et al. Roles of signaling pathways in the epithelial-mesenchymal transition in cancer. Asian Pac J Cancer Prev. 2015; 16: 6201-6.
24. Joannes A, Grelet S, Duca L, et al. Fhit regulates EMT targets through an EGFR /Src /ERK /Slug signaling axis in human bronchial cells. Mol Cancer Res. 2014; 12: 775-83.
25. Chou TY, Chen WC, Lee AC, et al. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK /Slug pathway. Cell Signal. 2009; 21: 704-11.
26. Ding Q, Miyazaki Y, Tsukasa K, et al. CD133 facilitates epithelialmesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Mol Cancer. 2014; 27: 13.